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Abstract The purpose of the study was to investigate the
expression of Aurora-A in human laryngeal squamous cell
carcinoma (LSCC) and to explore the eVects of Aurora-A
silencing on invasion and chromosomal instability in laryn-
geal cancer HEp-2 cells. The expression of Aurora-A
mRNA and protein were studied using reverse transcrip-
tion-PCR and Western blot in LSCC tissues and corre-
sponding normal epithelium, respectively. In addition, the
correlation between Aurora-A expression and clinicopatho-
logic characteristics was analyzed in LSCC patients. Fur-
thermore, HEp-2 cells were transfected with Aurora-A
short hairpin RNA and the eVects of knockdown of Aurora-
A on tumor invasion and chromosomal instability were
investigated. The results showed that expression of Aurora-
A mRNA was signiWcantly upregulated in laryngeal tumor
tissue compared with that in normal tissue (P =0 . 0 0 1 ) ,  a n d
overexpression of Aurora-A was found in 64.0% (16 of 25)
of the patients by Western blotting. Upregulation of
Aurora-A mRNA was signiWcantly correlated with regional
lymph node metastasis (P = 0.007) and clinical stage III/IV
(P = 0.022). Overexpression of Aurora-A was signiWcantly
associated with lymph node metastasis (P = 0.027). Fur-
thermore, disruption of Aurora-A using RNA interference
technique suppressed invasive ability and chromosomal
instability in HEp-2 cells. In conclusion, Aurora-A expres-
sion is elevated in human LSCC and associated with
regional lymph node metastasis and late clinical stage.
Overexpression of Aurora-A may contribute to LSCC
carcinogenesis and progression partially due to enhance-
ment of invasion ability and chromosomal instability.
Keywords Aurora kinase · Laryngeal neoplasms · 
Cell invasion · Chromosomal instability
Introduction
Laryngeal squamous cell carcinoma (LSCC) is a world-wide
malignancy and its survival rate is not improving. Since lar-
ynx has a crucial physiological function in respiration and
phonation, LSCC has a severe impact on the quality of life
of patients [1]. Despite recent advances in treatments, the
invasion and metastasis are still considered as the principal
reasons of mortality of LSCC patients. Currently the thera-
peutic strategies included surgical intervention, radiotherapy,
and chemotherapy, either alone or in combination.
However, they are less eVective in advanced cases. Therefore,
identifying new marker as tumor staging and new strategy
for the treatment of LSCC is in urgent demand.
Tumorigenesis is a multistep accumulation of genetic
alterations, driving indeWnite proliferation and malignant
transformation of normal human cells. The cellular mitoses
are controlled by several serine/threonine kinases, known
as mitotic kinases. Aurora-A is a member of the Aurora/
Ipl1p family of serine/threonine kinases, which is impli-
cated in concerted progression of each mitotic event.
Aurora-A ampliWcation was detected in breast, ovarian,
colon, prostate, neuroblastoma and cervical cancer cell
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lines. Ectopic expression of Aurora-A in mouse NIH 3T3
cells and human breast epithelial cells led to centrosome
ampliWcation and cell transformation in vitro [2]. Further-
more, a correlation between overexpression of Aurora-A
and tumor development has been described in colorectal
cancer and cervical cancer [3, 4]. These Wndings suggest
that Aurora-A is a pivotal kinase whose overexpression
leads to carcinogenesis in mammalian cells.
The expression of Aurora-A both in mRNA and protein
level in a series of LSCC patients was rarely reported. In
addition, the correlation between expression of Aurora-A and
clinical aggressiveness in cancers remains controversial. Fur-
thermore, the eVects Aurora-A exerts on tumor invasion and
chromosomal instability in laryngeal HEp-2 cells are not well
investigated. In this study, we examined the expression of
Aurora-A and its association with clinicopathologic features
in LSCC patients. We also delivered a speciWcally designed
short hairpin RNA (shRNA) targeting Aurora-A into laryn-
geal cancer HEp-2 cells, to evaluate the inhibitory eVect of
Aurora-A knockdown on cell invasion ability and chromo-
somal instability status in HEp-2 cells. The results showed
that Aurora-A was overexpressed in LSCC and Aurora-A
silencing by siRNA could eVectively inhibit the invasion and
chromosomal instability in HEp-2 cells.
Methods
Patients and clinical tissue samples
All tissues were obtained and kept in liquid nitrogen from
patients who were diagnosed with primary LSCC and
underwent a surgical procedure in the Department of
Otolaryngology-Head and Neck Surgery, Eye Ear Nose and
Throat Hospital, Fudan University from April to July in
2009. Written informed consents were obtained from the
patients regarding the surgical operation and the use of
resected specimens for research. All tumors were conWrmed
by the Department of Pathology of the hospital and were
classiWed according to the 3rd edition of TNM staging of
head and neck cancer [5]. Non-neoplastic squamous epithe-
lium which was at least 1 cm from the tumor margin was
used as paired normal adjacent tissues. Patients’ clinical
data were retrieved from medical records, including gender,
age, tumor site, tumor and lymph node classiWcation, histo-
logical grade and tumor stage. In addition, patients with
preoperative chemotherapy and radiation were excluded.
Extraction of tissue RNA and quantitative 
reverse transcription-PCR
Total RNA was extracted from the frozen stored tissues
of patients using the TRIzol reagent (Invitrogen, CA)
according to the manufacturer’s protocol. 2 g of total
RNA were reverse transcribed to cDNA using the
Reverse Transcription System (Promega, WI, USA).
cDNA sequence were then ampliWed by quantitative
PCR with SYBR Green (Invitrogen, CA). In brief, 1 l
of cDNA was added in a 20 l reaction mixture contain-
ing 2£ SYBR Green PCR Master Mix (Applied Biosys-
tem, CA). The PCR primers used for Aurora-A were 5-
ACT GAC CAC CCA AAA TCT GC-3 for the forward
primer and 5-TGG AAT ATG CAC CAC TTG GA-3
for the reverse primer, For glyceraldehyde-3-phosphate
dehydrogenase (GAPDH), the forward primer was 5-G
GA CCT GAC CTG CCG TCT AG-3, and the reverse
primer was 5-GTA GCC CAG GAT GCC CTT GA-3.
PCR conditions were 50°C for 2 min, and 95°C for
10 min, followed by 40 cycles at 95°C for 15 s, 59°C
for 60 s. The expression level of Aurora-A mRNA
was internally normalized using GAPDH. Aurora-A
mRNA level of tumor or normal tissue sample was
represented as 2¡Ct, in which the Ct represents
diVerence between thresholds of Aurora-A and GAPDH
(CtAurora-A¡Ct GAPDH).
Protein extraction and Western blotting assay
Frozen tissue samples were ground to a Wne powder using
a mortar and pestle under liquid nitrogen. Tissues were
then dissolved in T-PER Tissue Protein Extraction
Reagent (Thermo Fisher ScientiWc Inc., IL) on ice for at
least 30 min and centrifuged at 14,000g for 15 min at 4°C.
Protein concentration was determined using the BCA
Protein Assay Reagent (Thermo Fisher ScientiWc Inc.,
IL). 30 g of protein samples were loaded onto a 10%
SDS-PAGE. After electrophoresis, the separated proteins
were transferred to a PVDF membrane (BioRad, CA)
overnight at 4°C. Membrane was blotted with 5% non-fat
dry milk dissolved in 1£ TBS for 2 h in room tempera-
ture, and then incubated in 1:2,000 primary anti-Aurora-A
rabbit polyclonal antibody (Abcam, UK) overnight. After
washing with TBST and incubation with horseradish
peroxidase-conjugated antirabbit secondary antibody
(Abcam, UK) for 1 h diluted in 1:3,000, the protein bands
were detected using Immobilon Western chemilumines-
cent HRP substrate (Millipore, MA). The membrane was
stripped with 0.2 M NaOH and re-probed using GAPDH
antibody diluted in 1:3,000 (Abcam, UK). The band inten-
sity of Aurora-A and GAPDH were quantiWed by Alpha-
EaseFC software (Alpha Innotech, CA) and Aurora-A
expression of each specimen was determined by the ratio
of Aurora-A and GAPDH intensity. Afterward, for a spe-
ciWc clinical case the Aurora-A expression was calculated
as T/N ratio, i.e., Aurora-A in tumor/Aurora-A in corre-
sponding normal tissue.Eur Arch Otorhinolaryngol (2012) 269:607–614 609
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Cell cultures and shRNA transfection
Human laryngeal cancer HEp-2 cell line was grown in
RPMI1640 (Invitrogen, CA) supplemented with 10% fetal
bovine serum and 200 g/ml penicillin at 37°C under
5%CO2. Cells were re-fed with fresh medium every 2–3 days.
A chemically synthesized oligonucleotide encoding
Aurora-A (NM_003600) short hairpin RNA was inserted
downstream of U6 promoter of the pGC-silencer-U6/GFP/
Neo plasmid (pGC-shAurora-A) and cloned (Genchem,
China). The sequence of the oligonucleotide targeting
Aurora-A was 5-CAAAGAATCAGCTAGCAAA-3. A
non-speciWc stem-loop DNA vector (pGC-shNS) was also
generated for use as a negative control. HEp-2 cells were
transfected with pGC-shAurora-A or pGC-shNS with Lipo-
fectin reagent (Invitrogen, CA) according to the manufac-
turer’s instructions. BrieXy, HEp-2 cells (4 £ 105) were
plated into individual wells of six-well dish. 24 h later, 4 g
of plasmid and 10 l of Lipofectamine (Invitrogen, CA)
were added to 250 l of Opti-MEM (Invitrogen, CA),
respectively, and incubated for 5 min at room temperature.
Afterward, the plasmid and Lipofectamine solutions were
mixed gently and placed for 20 min. Then the mixture was
diluted with 2 ml RPMI with 10%FBS and added to the
well at 37°C under 5%CO2 for 24 h. Subsequently, the cells
were selected against G418 at a Wnal concentration of
800 g/ml for 3 weeks and stable Aurora-A knockout HEp-
2 cells were acquired.
Trans-well assay
Cell invasion was investigated with chemotaxis chambers
(Neuro Probe, Inc. Gaithersburg, MD). Cells (1 £ 105) in
200 l of RPMI1640 were added to the upper chamber and
500 l of RPMI1640 with 10%FBS was Wlled in the lower
chamber. A polycarbonate membrane with 8 m-diameter
pores was placed between the two chambers. The cells were
allowed to migrate at 37°C in a 5%CO2 humidiWed incuba-
tor. 24 h later, non-migrating cells on the upper chamber
were removed with a cotton swab. The Wlter membrane
were then Wxed in methanol for 10 min and stained with
Giemsa solution for 20 min. Migrated cells on the mem-
brane were counted under a microscope. Invasion was
quantiWed by counting the migrated cells in three random
Welds per Wlter.
Chromosome segregation analysis
For analysis of chromosomal instability events, cells on cham-
ber slides were washed with PBS, Wxed in methanol:acetic acid
(3:1) at ¡20°C for 30 min, air dried, and stained with hema-
toxylin and eosin. Anaphase cells showing at least one string of
chromatin connecting the poles were classiWed as harboring an
anaphase bridge. Anaphase cells with a chromosome conWgu-
ration showing three or more spindle poles were classiWed as
multipolar mitoses. At least 100 anaphase and metaphase cells
were analyzed in each group.
Statistical analysis
Aurora-A mRNA level between tumor and normal groups
was compared by independent-samples t test with a Statisti-
cal Product and Service Solutions software (SPSS, Inc.,
Chicago, IL). The association of tumor Aurora-A mRNA
and clinicopathologic characteristics was analyzed by t test
in two classes or Student–Newman–Keuls test between var-
ious groups. The relationship between Aurora-A protein
expression and clinicopathologic characteristics was ana-
lyzed by Fisher’s exact test in two groups and Pearson’s
Chi-square test in more than two groups. For cellular exper-
iments, statistical diVerences among groups were evaluated
using one-way ANOVA analysis. Statistical signiWcance
was considered at the value of P <0 . 0 5 .
Results
Aurora-A mRNA upregulation and protein 
overexpression in LSCC
To investigate whether Aurora-A abnormalities are related
to human LSCC, we Wrst analyzed expression level of
Aurora-A mRNA in clinical samples. Quantitative reverse
transcriptase-PCR was used in 37 tumor specimens and
their paired normal adjacent tissues. The mean expression
of Aurora-A mRNA was 0.0916 § 0.0924 (range
2.21 £ 10¡8 to 0.289) in tumor samples, and 0.0255
§ 0.0794 (range 4.11 £ 10¡8 to 0.298) in normal adjacent
tissues. Aurora-A mRNA expression level in LSCC was
signiWcantly higher than that of normal epithelium
(P = 0.001, Fig. 1a).
We then examined the Aurora-A protein expression in
tumor samples and their paired normal adjacent tissues. 25
patients’ paired samples were successfully analyzed by
Western blotting. We deWned the cases with a Aurora-A
protein T/N ratio over 1.20 as overexpression, whereas the
cases with a T/N ratio less than 1.20 were classiWed as non-
overexpression. Aurora-A overexpression was detected in
16 of 25 (64.0%) LSCC cases (Fig. 1b). The correlation
between Aurora-A overexpression and mRNA upregulation
was not found. We also examined expression of Aurora-A
protein in human LSCC HEp-2 cells. As shown in Fig. 1c,
HEp-2 cells revealed high expression of Aurora-A level as
HeLa cell did.610 Eur Arch Otorhinolaryngol (2012) 269:607–614
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Overexpression of Aurora-A is correlated 
with regional lymph node metastasis
The correlation between Aurora-A expression and patients
clinicopathological characteristics was examined. As sum-
marized in Table 1, Aurora-A mRNA upregulation was
correlated with regional lymph node metastasis (P = 0.007)
and clinical stage III/IV (P = 0.022). There was no signiW-
cant correlation between Aurora-A mRNA and patient’s
gender (P = 0.788), age (P = 0.305), tumor anatomy site
(P = 0.905), T category (P = 0.582), as well as pathological
grade (P = 0.814).
Aurora-A protein overexpression (T/N ratio > 1.20) was
signiWcantly associated with the occurrence of regional
lymph node (P = 0.027, Table 2). Correlation between
Aurora-A overexpression with patient’s gender
(P = 0.360), age (P = 0.411), tumor site (P = 0.172), T cate-
gory (P = 0.171), histological grade (P = 0.396) and clini-
cal stage III/IV (P = 0.097) were not found.
Suppression of Aurora-A inhibits HEp-2 cell invasion
As we found Aurora-A overexpression was correlated with
regional metastasis in clinical data, we further examined the
role of Aruora-A in HEp-2 cell invasion. Aurora-A shRNA
plasmid was constructed and transfected to HEp-2 cells to
knockdown endogenous Aurora-A. Aurora-A protein was
shown to be reduced after transfection (Fig. 2a). HEp-2/
Knockdown ratio for Aurora A protein was 2.31, exceeding
the threshold for T/N ratio we determined for clinical spec-
imens. In contrast, a non-speciWc shRNA was used as nega-
tive control and showed no Aurora-A suppression in the
experiment. With suppression of Aurora-A, cell invasion
capability was inhibited by 50% in Aurora-A shRNA trans-
fected HEp-2 cells compared with non-speciWc shRNA
transfected cells shown in Trans-well assay (P < 0.01,
Fig. 2b, c, d, e). Therefore, suppression of Aurora-A led to
inhibition of HEp-2 cell invasion.
Fig. 1 Expression of Aurora-A in 37 LSCC patients and HEp-2 cells.
a mRNA level of Aurora-A in tumor tissues and corresponding nor-
mal adjacent tissues was analyzed by quantitative reverse transcrip-
tase-PCR. Aurora-A mRNA level in LSCC was signiWcantly higher
than that of normal epithelium (*P =0 . 0 0 1 ) .   b Protein expression of
Aurora-A in LSCC samples (T) and their corresponding normal epi-
thelium (N) were investigated by Western blot. Aurora-A expression
in each patient was evaluated using T/N ratio (the ratio of Aurora-A in
tumor/Aurora-A in corresponding normal tissue). c Protein expression
of Aurora-A in HEp-2 cells. HeLa cells were used as positive control
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Table 1 Correlation between Aurora-A mRNA level and patients
clinicopathologic characteristics
a Independent-samples t test
Patients 
characteristics
Case 
number
Aurora-A 
mRNA level 
(mean)
SD P value
Gender
Male 36 0.0910 0.0935 0.788
Female 1 0.1166
Age
·64 23 0.1040 0.0905 0.305
¸65 14 0.0714 0.0950
Tumor site
Supraglottic 17 0.0853 0.0710 0.905
Glottic 13 0.1009 0.1082
Subglottic 7 0.0899 0.1182
T category
T1 6 0.0592 0.0485 0.582
T2 22 0.0983 0.0960
T3 8 0.1087 0.1094
T4 1 0.0035
Lymph node metastasis
N(¡) 23 0.0607 0.0737 0.007a
N(+) 14 0.1425 0.0997
Histologic grade
1 5 0.0669 0.0768 0.814
2 30 0.0961 0.0961
3 2 0.0872 0.1075
Clinical stage
I, II 19 0.0584 0.0739 0.022a
III, IV 18 0.1268 0.0985Eur Arch Otorhinolaryngol (2012) 269:607–614 611
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Knockdown of Aurora-A reduces abnormalities 
of chromosome segregation in HEp-2 cells
Aurora-A is an important regulator of bipolar spindle
assembly and therefore essential for accurate chromo-
some segregation. To evaluate the eVect of Aurora-A in
chromosome segregation in HEp-2 cells, cell division
morphology, demonstrated by anaphase bridges and mul-
tipolar mitoses, was analyzed. In Aurora-A shRNA trans-
fected cells, anaphase bridges only occurred in
6.3 § 1.5% of anaphase cells, whereas anaphase bridges
were present in 11.0 § 2.6% of non-speciWc shRNA
transfected cells (P < 0.01, Fig. 3a, b, c). Multipolar con-
Wgurations were also less frequently observed in Aurora-
A shRNA transfected cells than control cells (3.3 § 0.6%
vs. 6.7 § 0.6%, P <0 . 0 1 ,  F i g .3a, d). These Wndings sug-
gest that knockdown of Aurora-A reduced abnormal chro-
mosome segregation.
Discussion
In the present study, we examined the expression of
Aurora-A in human LSCC at mRNA and protein levels.
The results showed that expression of Aurora-A mRNA
and protein was signiWcantly increased in laryngeal cancers
compared with the most of the normal adjacent tissues.
Likewise, expression of Aurora-A was also high in laryn-
geal cancer line HEp-2 cells. Furthermore, upregulation of
Aurora-A mRNA was closely related to regional lymph
node metastasis and tumor stage. These data indicated that
alterations of Aurora-A at mRNA and protein levels are
common abnormality in LSCC and may play important
roles in LSCC progression.
Aurora-A is a mitotic-regulating serine/threonine kinase
and its overexpression was associated with various cancers,
including our series of laryngeal cancer patients. There are
a range of mechanisms by which Aurora-A overexpression
might promote tumor progression. Activation of Aurora-A
transcription or supression of protein degradation may
cause Aurora-A overexpression, resulting in tetraploid cells
with multiple centrosomes [6]. These tetraploid cells would
continue their division under inactivated p53-RB pathway
and impaired mitotic G1 checkpoint. In addition, overex-
pression of Aurora-A might interact with other cellular pro-
teins, such as PLK1, TPX2 and BRCA2, and induce
abnormal spindle formation and promote mitotic entry
through altering their physiological functions during
mitotic process [7–9]. The panorama of these signaling
pathways that Aurora-A involved in tumor progression
needs further investigation.
However, we found that high expression of Aurora-A
protein was not related to mRNA upregulation in the pres-
ent study. Similar discrepancies between ampliWcation and
overexpression rates were also reported in hepatocellular
carcinomas. Previous study found that ampliWcation of
Aurora-A was detected in only 3% of cases, but more than
60% of cases overexpressed Aurora-A protein in hepatocel-
lular carcinomas [10]. This discrepancy may be accounted
for that constitutive phosphorylation on Ser51 of Aurora-A
induces protein stabilization and consequent accumulation
in cancer cells, and exhibit overexpression of Aurora-A
protein [11]. Therefore, suppression of protein degradation
might be important for Aurora-A overexpression and its
oncogenic role. Thus, it might be speculated that the inhibi-
tion of Aurora-A phosphorylation represents a novel way to
decrease Aurora-A levels in cancer therapy.
In the aspect of cytogenetic mechanisms of tumorigene-
sis, it was well established that chromosomal instability
might create structural and numerical chromosome aberra-
tions [12]. The eVect of Aurora-A overexpression on chro-
mosomal instability to the progression of laryngeal cancer
cells is rarely studied. In the present study, chromosomal
Table 2 The relationship between Aurora-A protein expression and
patients clinicopathologic characteristics
a Fisher’s exact test
Patient 
characteristics
Non-overexpression 
(T/A ratio < 1.2)
Overexpression 
(T/A ratio ¸ 1.2)
P value
Gender
Male 8 16 0.360
Female 1 0
Age
·64 6 7 0.411
¸65 3 9
Tumor site
Supraglottic 4 5 0.172
Glottic 5 6
Subglottic 0 5
T category
T1 2 1 0.171
T2 7 9
T3 0 5
T4 0 1
Lymph node metastasis
N(¡)9 9 0 . 0 2 7 a
N(+) 0 7
Histologic grade
12 1 0 . 3 9 6
27 1 4
30 1
Clinical stage
I, II 7 6 0.097
III, IV 2 10612 Eur Arch Otorhinolaryngol (2012) 269:607–614
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instability events, i.e., anaphase bridge and multipolar
mitoses, were measured in anaphase and metaphase HEp-2
cells. The abnormal chromosome segregation was high in
HEp-2 cells and remarkably reduced in HEp-2 cells with
suppression of Aurora-A. One possible interpretation might
be that the Wdelity of chromosome segregation is assured in
the circumstances of G2/M checkpoint restoration by
Aurora-A suppression. The mutated aneuploid cells were
eliminated to the cell cycle. Consequently, the chromo-
somal instability is prevented. On the contrary, Aurora-A
overexpression induces a high level of chromosomal insta-
bility that favors the genomic alteration and tumor progres-
sion. Thus, our results may shed some light on the
mechanism by which overexpression of Aurora-A contrib-
utes to tumor progression in laryngeal cancer.
We observed that upregulation of Aurora-A is closely
related to regional lymph node metastasis and tumor stage
in clinical data. To further clarify whether Aurora-A con-
tributes to the ability of cell invasion, disruption of endoge-
nous Aurora-A protein through RNA interference
technique was used in HEp-2 cells. Trans-well assay
showed substantially suppression of cell invasion in
Aurora-A depleted HEp-2 cells. On the other hand since
invasion of tumor cells are essential prerequisites for the
metastatic process, invasion and metastasis of tumor to
neighboring organs is a main cause of the mortality of
LSCC patients. Therefore, these results further suggested
that overexpression of Aurora-A might play a major role in
regional lymph node metastasis and prognosis of patients.
Nevertheless, tumor metastasis is a complex process,
involving alterations of cells physical coupling to their
microenvironment and activation of extracellular proteases,
such as matrix metalloproteinase (MMP), as well as degra-
dation of extracellular matrix [13]. A recent research
revealed that MMP-2 and MMP-9 were highly expressed in
LSCC patients [14]. However, the signaling pathways
interacted between Aurora-A and MMPs in LSCC meta-
static mechanisms need further investigation.
The relationship between overexpression of Aurora-A
and tumor grade or tumor stage is controversial. Previous
Fig. 2 Transfection of Aurora-
A shRNA and Trans-well assay 
in HEp-2 cells. a Expression of 
Aurora-A was suppressed in 
HEp-2 cells transfected with 
Aurora-A shRNA detected by 
Western blot. GAPDH was used 
as internal control. A representa-
tive result of three independent 
experiments was showed. 
b Invasion of untransfected 
HEp-2 cells in Trans-well assay 
(£100). c Invasion of non-
speciWc shRNA transfected 
HEp-2 cells (£100). d Invasion 
of Aurora-A shRNA transfected 
HEp-2 cells (£100). e The 
number of migrated HEp-2 cells 
transfected with Aurora-A shR-
NA was signiWcantly less than 
those of untransfected cells. The 
number was expressed as 
mean § SD from three indepen-
dent experiments. (*P <0 . 0 1 ,  
Student–Newman–Keuls test)
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study argued that activation or overexpression of Aurora-A
protein was related to low grade and early stage of gastric
cancer and ovarian cancer [15, 16]. Moreover, Aurora-A is
preferentially expressed in less invasive tumors and
declines once a tumor becomes invasive. Other studies
showed that elevated expression of Aurora-A was strongly
associated with high histological grade and late stage in
skin and hepatocellular tumor [10, 17]. In the present study,
we observed that upregulation of Aurora-A mRNA was sta-
tistically correlated with clinical stage III/IV of LSCC.
Aurora-A protein was also overexpressed in patients of
tumor stage III/IV, although there was no statistic signiW-
cance between early stage and late stage tumors. Clinically,
when a LSCC patient has regional lymph node metastasis,
corresponding to N1–N3, the tumor was classiWed as stage
III or stage IV. Therefore, besides the role of Aurora-A in
lymph node metastasis, we supported the view that upregula-
tion of Aurora-A may also be associated with the develop-
ment of LSCC. This raised the possibility that Aurora-A
kinase inhibition may provide for a new approach for the
treatment of laryngeal cancer. Future studies are needed to
investigate the tumorigenicity of HEp-2 cells by RNA inter-
ference-mediated knockdown of Aurora-A alone or in combi-
nation with chemotherapeutic agents either in vitro or in vivo.
In conclusion, our Wndings suggest that expression of
Aurora-A is elevated in human LSCC and is associated
with regional lymph metastasis and late stage of tumor.
Suppression of Aurora-A reduces invasion ability and chro-
mosomal instability in HEp-2 cells. Thus, overexpression
of Aurora-A may contribute to LSCC carcinogenesis and
regional metastasis, and could be a potential molecular tar-
get for the gene therapy of LSCC.
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